Match each clinical presentation of an opportunistic infection in a patient with advanced HIV to the most appropriate first-line induction or targeted pharmacological therapy.
- CD4 count < 100/mm³; positive serum cryptococcal antigen; cerebrospinal fluid analysis shows encapsulated yeast on India ink stain.Induction therapy with liposomal amphotericin B and flucytosine
- CD4 count < 100/mm³; altered mental status; MRI of the brain demonstrates multiple ring-enhancing lesions with surrounding edema.Targeted therapy with sulfadiazine, pyrimethamine, and leucovorin
- CD4 count < 50/mm³; patient reports floaters and blurred vision; fundoscopic examination reveals yellowish-white exudates and perivascular hemorrhage.Targeted therapy with oral valganciclovir or intravenous ganciclovir
- CD4 count < 50/mm³; persistent fever, severe weight loss, watery diarrhea; blood cultures grow non-tuberculous acid-fast bacilli.Targeted therapy with a macrolide (e.g., clarithromycin) and ethambutol
Cevap
Cryptococcal meningitis pairs with amphotericin B and flucytosine. Toxoplasmic encephalitis pairs with sulfadiazine, pyrimethamine, and leucovorin. CMV retinitis pairs with valganciclovir. Disseminated MAC pairs with clarithromycin and ethambutol.
Each clinical scenario presents a classic manifestation of a specific opportunistic infection in a patient with HIV, which dictates a highly specific first-line antimicrobial regimen according to current clinical guidelines.
Adım Adım Çözüm
Anahtar Kavram
Targeted pharmacological treatment regimens for major opportunistic infections in advanced HIV.
Tahmini Süre:1m 30s